The current stock price of SCLN is 11.15 null. In the past month the price increased by 0.45%. In the past year, price increased by 11.39%.
Sciclone Pharmaceuticals, Inc. develops and commercializes novel medicines for treating a broad range of the world's most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C, hepatocellular carcinoma, malignant melanoma, hepatitis B, HIV, drug-resistant tuberculosis, cystic fibrosis and others.
SCICLONE PHARMACEUTICALS INC
950 TOWER LANE SUITE 900
FOSTER CITY CA 94404
CEO: Friedhelm Blobel
Phone: 650-358-3456
Sciclone Pharmaceuticals, Inc. develops and commercializes novel medicines for treating a broad range of the world's most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C, hepatocellular carcinoma, malignant melanoma, hepatitis B, HIV, drug-resistant tuberculosis, cystic fibrosis and others.
The current stock price of SCLN is 11.15 null.
SCLN does not pay a dividend.
SCLN has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
SCLN stock is listed on the Nasdaq exchange.
ChartMill assigns a technical rating of 6 / 10 to SCLN. When comparing the yearly performance of all stocks, SCLN turns out to be only a medium performer in the overall market: it outperformed 64.39% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to SCLN. SCLN has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months SCLN reported a non-GAAP Earnings per Share(EPS) of 0.8174. The EPS increased by 9.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25.18% | ||
| ROA | 15.6% | ||
| ROE | 17.34% | ||
| Debt/Equity | 0 |